Last Updated : October 30, 2024
Details
FilesGeneric Name:
eltrombopag
Project Status:
Complete
Therapeutic Area:
Severe Aplastic Anemia (SAA)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0777-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
For the treatment of
adult patients with severe aplastic anemia (SAA).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | April 17, 2023 |
|---|---|
| Call for patient/clinician input closed | June 12, 2023 |
| Clarification: - Patient input submission received from Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC) | |
| Call for industry input open | April 17, 2023 |
| Call for industry input closed | June 12, 2023 |
| Submission received | April 13, 2023 |
| Review initiated | May 24, 2023 |
| Expert committee meeting (initial) | October 17, 2023 |
| Draft recommendation posted for stakeholder feedback | November 09, 2023 |
| End of feedback period | November 24, 2023 |
| Final recommendation posted | December 20, 2023 |
| CADTH review report(s) posted | October 23, 2023 |
Files
Last Updated : October 30, 2024